A women’s health client was considering how to expand a label for an approved product with potential side effects that had traditionally garnered FDA concern. The client asked Catalyst to inform its regulatory strategy through a series of meetings, involving external experts, to discuss potential additional data collection needs, understand international clinical trial data expectations, and steps to best position the product’s application.
Sign up for periodic updates on regulatory policy and events we are attending
